ストックスクリーナーアプリを入手
0.4998
15.11%
0.0656
アフターアワーズ：
.49
-0.0098
-1.96%
前日終値:
$0.4342
開ける：
$0.457
24時間の取引高:
455.25K
Relative Volume:
1.11
時価総額：
$12.00M
収益：
当期純損益:
$-21.54M
株価収益率:
-0.5046
EPS:
-0.9904
ネットキャッシュフロー:
$-19.60M
1週間 パフォーマンス:
-26.39%
1か月 パフォーマンス:
-49.19%
6か月 パフォーマンス:
-76.75%
1年 パフォーマンス:
-93.62%
1日の値動き範囲:
$0.4326
$0.55
1週間の範囲:
$0.41
$0.6801
52週間の値動き範囲:
$0.41
$8.2652
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Compare ACTU vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
0.4998 | 12.00M | 0 | -21.54M | -19.60M | -0.9904 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-26 | 開始されました | B. Riley Securities | Buy |
| 2025-04-22 | 開始されました | Craig Hallum | Buy |
| 2025-03-17 | 開始されました | H.C. Wainwright | Buy |
Actuate Therapeutics Inc (ACTU) 最新ニュース
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Actuate Therapeutics to sell 50 million shares at assumed $0.819 price - scanx.trade
Actuate Therapeutics Registers 50 Million Shares for Public Offering at $0.819 Each - Kalkine Media
At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. - Stock Titan
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - Quiver Quantitative
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - careplusvn.com
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseEarnings Recovery Stocks - dars.gov.et
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseSurprise Factor Analysis - dars.gov.et
Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionEarnings Revision Downgrade - https://www.dars.gov.et/
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn
Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceInverse ETF Flow - dars.gov.et
Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - vinanet.vn
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics (ACTU) Pushes 3.58% Higher, Tests $1.06 Resistance ZoneButterfly Setup - dars.gov.et
Actuate Therapeutics (ACTU) Pushes 3.58% Higher, Tests $1.06 Resistance ZoneQuote Data - vinanet.vn
Actuate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) Holds Near $0.97 as Support Test LoomsButterfly Setup - vinanet.vn
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentEarnings Outlook Update - Vinanet
ETFs Investing in Actuate Therapeutics, Inc. Stocks - TradingView
Actuate Therapeutics Inc (ACTU) Stock News Today - TradingKey
Actuate Therapeutics (ACTU) Surges 8.85% to $1.23 as Buyers Defend Key SupportOvernight Profile - vinanet.vn
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Actuate Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACTU - TradingView
Rodman & Renshaw Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $6 - Moomoo
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics Inc (ACTU) Cash Flow - TradingKey
Actuate Therapeutics Inc (ACTU) Balance Sheet - TradingKey
Actuate Therapeutics Inc (ACTU) Income Statement - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.140|Chg%:-0.040 - TradingKey
Actuate Therapeutics Inc (ACTU) 財務データ
収益
当期純利益
現金流量
EPS
Actuate Therapeutics Inc (ACTU) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SCHMITT DANIEL M | President, CEO and Director |
Feb 13 '26 |
Option Exercise |
0.00 |
272,055 |
0 |
272,055 |
| THOMSON TODD S | Director |
Jan 05 '26 |
Sale |
5.80 |
280,000 |
1,624,000 |
904,795 |
| Kairos Venture Partners II, L. | Affiliate |
Dec 11 '25 |
Proposed Sale |
7.60 |
280,000 |
2,128,000 |
0 |
1.49%
大文字化:
|
ボリューム (24 時間):